Anti-BDCA2 Antibody Engineering for IFNα and IgM Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing BDCA2-targeting therapeutics for autoimmune diseases exhibit limitations, necessitating the development of novel anti-BDCA2 antibodies that effectively modulate plasmacytoid dendritic cell activity to suppress Type I interferon and pro-inflammatory cytokine release.
Innovation Solution
Development of an anti-BDCA2 antibody with specific heavy and light chain variable regions, including defined complementarity determining regions, which can be humanized and engineered to maintain high affinity and inhibitory efficacy against BDCA2, thereby regulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing BDCA2-targeting therapeutics are used for autoimmune diseases, then some therapeutic effect is achieved, but their efficacy is limited and cannot sufficiently suppress Type I interferon and pro-inflammatory cytokine release
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure to achieve superior binding affinity to BDCA2. The engineered anti-BDCA2 antibody incorporates specific heavy and light chain variable regions with optimized complementarity determining regions (CDRs), resulting in enhanced binding characteristics that improve therapeutic efficacy and suppress cytokine release more effectively than existing therapeutics
2Reliability
If an anti-BDCA2 antibody with high binding affinity is developed, then inhibitory efficacy against BDCA2 is improved, but the complexity of antibody engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional components: heavy chain variable region, light chain variable region, and constant regions. Each segment is independently engineered and optimized, with specific CDRs designed to achieve high binding affinity while maintaining modular construction that manages engineering complexity
Solution Approach 2:
The patent applies local quality by optimizing specific regions of the antibody (the CDRs in the variable regions) to achieve high binding affinity, while keeping other regions standardized. The H-CDRs and L-CDRs are specifically engineered with particular amino acid sequences to maximize BDCA2 binding, while the constant regions maintain typical immunoglobulin structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-BDCA2 antibody effectively inhibits CpG-A-induced secretion of IFNα and IgM, offering superior performance compared to existing agents, and is applicable for treating autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis.
Implementation Method 1
an anti-BDCA2 antibody... that binds to BDCA2
Implementation Method 2
Triggering of BDCA2 activates SYK protein, leading to the activation of a complex composed of BLNK, BTK, and PLCγ2, which subsequently mobilizes intracellular Ca2+
Implementation Method 3
The anti-BDCA2 antibody effectively inhibits CpG-A-induced secretion of IFNα and IgM
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody is capable of binding to the BDCA2 antigen with high specificity, exhibits high affinity, effectively inhibits CpG-A-stimulated secretion of IFNα and IgM by PBMCs, showing potential as a therapeutic agent for autoimmune diseases.